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Pseudoxanthoma elasticum (PXE) is a heritable ectopic mineralization disorder caused by loss-of-function mutations in the
ABCC6 gene which is primarily expressed in the liver. There is currently no eﬀective treatment for PXE. In this study, we
characterized bone marrow derived mesenchymal stem cells (MSCs) and evaluated their ability to contribute to liver regeneration,
with the aim to rescue PXE phenotype. The MSCs, isolated from GFP-transgenic mice by magnetic cell sorting, were shown to
have high potential for hepatic diﬀerentiation, with expression of Abcc6, in culture. These cells were transplanted into the livers
of 4-week-old immunodeficient Abcc6−/− mice by intrasplenic injection one day after partial hepatectomy, when peak expression
of the stromal cell derived factor-1 (SDF-1) in the liver was observed. Fluorescent bioimaging analyses indicated that transplanted
MSCs homed into liver between day 1 and 7, and significant numbers of GFP-positive cells were confirmed in the liver by
immunofluorescence. Moreover, enhanced engraftment eﬃciency was observed with MSCs with high expression levels of the
chemokine receptor Cxcr4, a receptor for SDF-1. These data suggest that purified MSCs have the capability of diﬀerentiating into
hepatic lineages relevant to PXE pathogenesis and may contribute to partial correction of the PXE phenotype.

1. Introduction
Pseudoxanthoma elasticum (PXE), a life-altering and frequently devastating disease, aﬀects the skin, the eyes, and
the cardiovascular system with ectopic mineralization [1, 2].
PXE is caused by the mutations in the ABCC6 gene, which
encodes a member of the C-family of ATP-binding cassette
transporters [3, 4]. Surprisingly, this gene appears to be
expressed primarily in the liver and the kidneys, tissues
not clinically aﬀected in PXE [5]. We have developed an
Abcc6 −/− mouse model by targeted ablation of the Abcc6
gene [6]. These mice recapitulate histopathologic features
of human PXE, and serve as an excellent model system to
study pathomechanisms leading to tissue mineralization as a
result of Abcc6 inactivation, and they serve as a platform to
evaluate the curative eﬀects of diﬀerent treatment modalities.
Recently, we have demonstrated that PXE is a metabolic
disorder with the primary pathology in the liver and with

secondary involvement of elastic fibers in soft tissues [7, 8].
However, the precise function of ABCC6 protein, consequences of the ABCC6 mutations at the mRNA and protein
levels, and the pathomechanisms leading to mineralization
of the elastic fiber structures are largely unknown. Currently,
there are no treatment modalities available for this disorder.
Various therapeutic strategies have been explored in
clinical trials based on cutting-edge basic research on liver
metabolic diseases. Gene therapy and cellular therapy are
overlapping fields of biomedical research with similar therapeutic goals of tissue regeneration. However, relatively little
progress has been made in gene therapy since the first clinical
trial in 1990 [9]. Short-lived nature of gene therapy and
problems of safety with viral vectors have kept gene therapy
from becoming an eﬀective treatment for many genetic
diseases [10, 11]. Liver transplantation might be an eﬀective
therapy for severe liver diseases, but few patients can benefit
from this procedure due to the shortage of donor organs.
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Moreover, the whole organ transplantation involves major
surgery, is highly invasive and requires lifelong immunosupression. Currently, cellular therapy with stem cells and their
progeny is a promising new approach capable of addressing
mostly unmet medical needs. The considerable excitement
surrounding the stem cell field is based on the unique
biological properties of these cells and their capacity to selfrenew and regenerate tissue and organ systems. Specifically,
bone marrow stromal cells are an attractive source for cellbased gene therapy to genetic liver disorders, and their
capability of diﬀerentiating into hepatocyte lineage has been
demonstrated previously [12, 13]. The cell transplantation
has been performed in several patients with modest liver
metabolic correction, such as in the patients with CriglerNajjar syndrome and with advanced liver failure [14–16].
It appears, therefore, that PXE would be an appropriate
candidate disease to test cell-based therapeutics.
Hereby, we preliminarily evaluated a stem-cell-based
therapeutic approach for PXE by assessment of the potential
of MSCs in liver reconstitution with the aim to rescue the
PXE phenotype in Abcc6 −/− mice and eventually on patients.

2. Materials and Methods
2.1. Mice and Cell Transplantation. An immunodeficient
PXE mouse model [8], generated by crossbreeding the traditional Abcc6 −/− mouse [6] with a well-established immunodeficient Rag1−/− mouse in C57BL/6 background (strain:
002216F; The Jackson Laboratory, Bar Harbor, ME), was
used in this study. four-week-old mice were anesthetized and
50% partial hepatectomy (PHx) was performed following the
standard protocol of Higgins and Anderson [17]. For the
administration of cells, approximately 5 × 105 Cxcr4-MSCs
or unmodified MSCs (see below) at passage 6, isolated from
GFP-transgenic mice (C57BL/6-Tg UBC-GFP; The Jackson
Laboratory) as the source of donor cells, were delivered into
the recipient mouse liver by intrasplenic injection at 24 hours
after PHx. The mice were maintained under pathogen-free
conditions and were handled in accordance with the guidelines for animal experiments by the Institutional Animal
Care and Use Committee of Thomas Jeﬀerson University.
2.2. Bone Marrow Derived Stem Cell Isolation and Characterization. The method of magnetic cell sorting (MACS)
was utilized to obtain desired populations of bone marrow
derived mesenchymal stem cells (MSCs) as described by
manufacturer (Miltenyi Biotec, Cambridge, MA). Briefly,
wild-type mouse MSCs were harvested from 4-week-old
GFP-transgenic mice and enriched by immunomagnetic separation strategies using cocktails of antibodies that deplete
the diﬀerentiated cells of hematolymphoid lineages (Lin),
such as the cells expressing the following lineage antigens:
CD5, CD45R, CD11b, Gr-1, 7-4, and Ter-119. To obtain a
pure population of stem cells, positive selection with Sca1 antibody was utilized to further sort cells by MACS.
These cells were maintained in the MSC medium containing
MesenCult MSC Basal Medium (Stemcell Technologies, Vancouver, Canada), 20% Mesenchymal Stem Cell Stimulatory
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Supplements (Stemcell Technologies), 100 unit/mL penicillin (Invitrogen, Carlsbad, CA), 100 μg/mL streptomycin
(Invitrogen), and 2.5 μg/mL amphotericin B (Invitrogen).
The culture medium was changed every 3 days. Mouse MSCs
at passage 6, identified as Lin− CD45− CD31− Sca-1+ , were
used as MSCs for the experiments.
To characterize the cell surface markers by flow cytometric analysis, harvested MSCs were incubated at 4◦ C for 30
minutes with rat anti-mouse CD11b, CD45, CD105, CD106,
Sca-1, CD29, or MHC-1 antibody (R&D system, Minneapolis, MN), followed by 30 minutes incubation with APClabeled rabbit anti-rat IgG antibody (BD Biosciences, San
Jose, CA). Cells were examined by using FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ) and data
were analyzed with Flowjo software (Tree Star Inc., Ashland,
OR).
2.3. Transfection and Selection of MSCs Expressing Exogenous
Cxcr4. MSCs at approximately 80% confluency were transfected with pCMV6-Kan/Neo carrying a full length cDNA of
mouse Cxcr4 (Origene, Rockville, MD) using Lipofectamine
transfection reagent (Invitrogen) according to the manufacturer’s instructions. The transfected cells were maintained in
the MSC medium and subjected to the selection by G418 at
the dose of 1,500 μg/mL, and switched to the maintenance
dose of 500 μg/mL in 2 weeks. The positive transfected cells
were described as Cxcr4-MSCs in subsequent experiments.
2.4. In Vitro Hepatic Diﬀerentiation. Prior to starting the
hepatic diﬀerentiation, MSCs at passage 5 were maintained in the regular MSC culture medium until at 80–
90% confluence. The hepatic diﬀerentiation was elicited in
the diﬀerentiation-inducing medium, which consisted of
DMEM (Invitrogen) supplemented with 10% FBS, 10 ng/mL
hepatocyte growth factor (HGF) (PeproTech Inc, Rocky Hill,
NJ), 10 ng/mL basic fibroblast growth factor (bFGF) (PeproTech INC) and 10 ng/mL oncostatin M (R&D system). The
medium was changed every 3 days, and the cells were
cultured for 8 days.
2.5. Immunofluoresence. To analyze the protein expression in
the diﬀerentiated MSCs, the cells either in the regular MSC
culture medium or in the diﬀerentiation-inducing medium
were fixed in 4% paraformaldehyde and then permeabilized
with 0.1% Triton X-100 at day 8. The cells were incubated
with mouse anti-human mouse albumin (Alb) antibody
(R&D system) or rabbit anti-mouse cytokeratin (CK)-18
antibody (Novus, Littleton, CO), followed by the incubation
with the second antibody, Texas Red conjugated anti-rabbit
IgG (Molecular Probe, Eugene, Oregon). DAPI was used for
nuclear counterstaining.
To examine the presence of GFP positive transplanted
MSCs in the liver, the engrafted livers were removed, fixed
with 4% paraformaldehyde, processed in a gradient sucrose,
and then subjected to immunofluorescent analysis. The processed livers were embedded in Tissue-tec OCT Compound
(Sakura Finetechnical Co., Ltd., Tokyo, Japan), and stored
at −80◦ C until use. Six-μm-thick frozen sections of the liver
were incubated with rabbit anti-GFP antibody (Invitrogen).
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Subsequently, sections were stained with FITC goat anti
rabbit IgG secondary antibody (Invitrogen).
2.6. RT-PCR and qPCR. To examine the liver specific gene
expression in diﬀerentiated MSCs, total RNA was extracted
from the cultured regular MSCs or the diﬀerentiated MSCs
at day 8 of culture using RNeasy Mini Kit (Qiagen, Hilden,
Germany). RNA samples were subjected to random-primed
reverse transcription by using the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen). RT reaction
products were used for PCR for amplifying mouse CK-18,
hepatocyte nuclear factor (HNF)-3b and Abcc6, with actin
as an internal control. To analyze the expression of Cxcr4 in
the transfected cells with pCMV6-Cxcr4 plasmid, RNA isolation and reverse transcription procedures were performed
as above with on-column DNA digestion. The PCR was
performed to amplify mouse Cxcr4 gene in transfected or
untransfected cells with Gapdh as an internal control.
To quantitate the percentage of migrated GFP positive
MSCs into the liver by qPCR, total DNA was extracted from
homogenized engrafted liver using the DNeasy Kit (Qiagen).
SYBR Green PCR amplification of GFP was performed in
ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA) using SYBER Green PCR Master
Mix (Applied Biosystems). The amount of GFP+ DNA in
each 50 ng DNA sample was quantified and normalized
to interleukin (IL)-2 DNA. The relative expression level of
the target gene was calculated using the ΔΔCt method. To
prepare the standard curve, genomic DNA from the wild
type mouse was spiked with serial dilutions of genomic DNA
from the GFP-transgenic mouse. The diluted GFP standard
samples were subjected to the PCR amplification of GFP and
IL-2, and the percentage of GFP transgene per 50 ng tissuederived DNA was calculated.
2.7. ELISA for Murine SDF-1. Serum samples were collected
from the mice before PHx, and at 2 hours, 1 day, 3 days, and
7 days after the surgery. SDF-1 levels of mouse serum were
determined using the mouse SDF-1 ELISA Kit (R&D system)
according to the manufacturer’s instructions. Liver samples
were harvested from mice at the designated time points after
the surgery and homogenized using a homogenizer and a 27
gauge needle in the RIPA buﬀer (Sigma-Aldrich, St. Louis,
MO) supplemented with the proteinase inhibitor cocktail
(Complete, Mini; Roche Applied Science, Indianapolis, IN)
at 4◦ C. The mixture was centrifuged for 20 minutes at
12,000 rpm at 4◦ C and the supernatant was collected. The
SDF-1 concentration in the liver extracts was examined
by using the mouse SDF-1 ELISA Kit (R&D system) and
normalized by the total protein concentration measured by
BCA Protein Assay Kit (Pierce, Rockford, IL).
2.8. Migration Determination In Vitro and In Vivo. In vitro
migration assays were carried out in a 48-well transwell using
polycarbonate membranes with 8-μm pores (Osmonics;
Livermore, CA). After diﬀerent concentrations of mouse
recombinant SDF-1 (R&D system) were added to the lower
chamber, 2.5 × 103 MSCs or Cxcr4-MSCs in 30 μL of
DMEM with 0.5% FBS were placed in the upper chamber
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of the transwell assembly. After incubation at 37◦ C and 5%
CO2 for 4 hours, the upper surface of the membrane was
scraped gently to remove nonmigrating cells and washed
with PBS. The cells on the membrane were fixed in 4%
paraformaldehyde for 15 minutes and stained with Giemsa.
The number of migrating cells was determined by counting
3 random fields per well under the microscope at 100x
magnification. Experiments were performed in triplicate.
To assess the in vivo migration ability of MSCs, fluorescence bio-imaging system was utilized. The mice transplanted with MSCs labeled with a fluorescent dye, Vybrant
DiD (Molecular Probes, Eugene, OR) were monitored at
multiple time points (day 1, week 1, week 2, and week 3)
by using an IVIS Luminar XR live imaging system (Caliper,
Hopkinton, MA) at excitation filter 644 nm and emission
filter 665 nm.
2.9. Data and Statistical Analysis. Statistical analyses were
performed with Student’s t-test. P values <0.05 were considered statistically significant.

3. Results and Discussion
3.1. MSC Isolation and Cell-Surface Antigen Profile. Total
bone marrow from GFP-transgenic mice was obtained by
purging the medullar canal of the femurs and tibias with a
26 gauge needle, and MSCs were purified by magnetic cell
sorting using antibodies against a panel of hematolymphoid
lineage antigens for negative selection and then antibodies
against Sca-1 for positive selection (see Section 2). Flow
cytometric analysis of freshly isolated cells demonstrated
that approximately 99% cell populations were both GFP and
Sca-1 positive (data not shown). The cells were cultured in
the regular MSC medium and passaged when they reached
80% confluence. Under the microscopic observation, the
cells at early passage (passage 3) exhibited a thin spindle
like shape and became large fibroblast-like in a swirl pattern
at passage 5 (Figure 1(a)). Flow cytometric analyses showed
a positive histogram peak for Sca-1 and CD29, but both
positive and negative histogram peaks for CD11b, CD45,
and CD106 were observed with the cells at passage 3. The
histogram positive peak for CD11b and CD45, and negative
peak for CD106 disappeared at passage 5 (Figure 1(b)).
These observations indicated the presence of two populations: hematopoietic stem cells (HSCs) and MSCs, and
that a significant enrichment in MSCs was gained during
subsequent culturing of the cells. MSCs have been shown
to be a resource of hepatic diﬀerentiation, but there are
no specific markers of MSCs. Thus, to obtain purified
population of MSCs, a further purification may be needed
by in vitro culture following selection using by a group of
surface markers.
The cells at passage 3, 5, or 7 were also analyzed by
FACS for their immunologic properties using monoclonal
antibody to mouse MHC class I. MSCs (passage 3, 5, and
7) derived from the same mouse expressed high levels of
MHC class I when compared to melanoma derived cells (BLTAC, negative control) and mouse fibrosarcoma derived cells
(MC57G, positive control) (Figure 2). In the literature, it has
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Figure 1: Characterization of the mouse bone marrow derived stem cells. The bone marrow derived stem cells were isolated by magnetic cell
sorting using a Lin− cocktail of antibodies as well as stem cell antigen-1 (Sca-1) antibody and then cultured in the regular stem cell culture
medium. (a) The cells were observed by phase contrast microscopy at passage 3 (left) or passage 5 (right). The cells at passage 5 became
more fibroblastic appearing compared to passage 3. (b) Flow cytometry was utilized to examine the surface markers of cells at passage 3 (top
panels) or passage 5 (bottom panels) for the purity of cell population.
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Figure 2: Flow cytometric characterization of MHC class I expression in bone marrow derived stem cells. The cells at passage 3 (MSC-p3),
5 (MSC-p5) or 7 (MSC-p7) were analyzed by FACS using monoclonal antibody to mouse MHC class I. Mouse melanoma derived cells
(BL-TAC) and mouse fibrosarcoma derived cells (MSC57G) were used as negative and positive controls, respectively.

been suggested that MSCs may be immunoprivileged and
can be transplantable between MHC-incompatible individuals [18]. On the other hand, it has been suggested that
MSCs are not intrinsically immunoprivileged and could not
serve as a “universal donor” in immunocompetent MHCmismatched recipients [19]. In our study, high expression of
MHC class I supported the latter possibility and suggested
that modulation of immune response may be of concern
when these cells are employed in vivo.
3.2. Diﬀerentiation Potential of Bone Marrow Stem Cells into
Hepatocytes In Vitro. To investigate the potential of hepatic
diﬀerentiation of MSCs, the purified MSCs at passage 6 were
cultured for 8 days in diﬀerentiation-inducing medium, that
is, DMEM containing 10% fetal bovine serum, 10 ng/mL
HGF, 10 ng/mL bFGF, and 10 ng/mL oncostatin M. The cell
morphology changed as they became extended and larger
(Figure 3(a), top panel). Immunofluorescence analysis was
performed for the expression of the hepatocyte-specific proteins and demonstrated that CK-18 and Alb were positively
expressed in the diﬀerentiated cells but not in the undiﬀerentiated ones (Figure 3(a), middle and bottom panels). HNFs
and CK-18, key players for the hepatogenesis, were expressed
in the diﬀerentiated cells by RT-PCR, while negative in
control cells cultured with the MSC culture medium for

the same period (Figure 3(b)). MSCs, maintained either in
diﬀerentiation-inducing medium or under basal condition,
expressed Abcc6 mRNA at comparable levels.
The diﬀerentiation process of stem cells requires a
specific microenvironment. The results clearly demonstrated
that the isolated mouse MSCs are able to diﬀerentiate
into hepatocytes under in vitro conditions in medium
containing growth factors HGF, bFGF and oncostatin M,
which have been reported to be important components for
liver development and diﬀerentiation [20, 21]. In addition,
our diﬀerentiated cells could show the expression of the
Abcc6 gene, which is lost in PXE and may be needed to restore
its phenotype. These data provide critical information about
stem cell biology that should contribute to the development
of regenerative medicine for liver diseases in general and for
PXE in particular.
3.3. Migration Capability of Bone Marrow Stem Cells
3.3.1. MSCs Cxcr4 Expression and In Vitro Migration. MSCs
at passage 4 were transfected with a murine Cxcr4 expression
vector driven by CMV promoter, pCMV6-mCxcr4, and then
selected with G418 to obtain cells with stable expression
(Cxcr4-MSCs). The Cxcr4-MSCs were analyzed for expression of Cxcr4 first by RT-PCR. High level of Cxcr4 mRNA
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Figure 3: Hepatocytic diﬀerentiation capacity of mouse bone marrow stem cells in vitro. The cells at passage 5 were cultured either in
the regular stem cell culture medium (a, left panels) or in the diﬀerentiation-inducing medium (a, right panels). As observed by phase
contrast microscopy at day 8 (top panels), the cells became extended and larger in the diﬀerentiation-inducing medium (a, right top).
Immunofluorescent analysis was performed at day 8 of diﬀerentiation. Cells were stained with antibodies to liver-specific marker proteins,
albumin (a, middle panels), or CK-18 (a, bottom panels). DAPI staining was used to identify the nuclei (blue). Strong signals were observed
in the cells cultured in the diﬀerentiation-inducing medium (a, right middle and bottom panels), while weak signal (a, left middle and
bottom panels), if any, was detected in the cells cultured in the regular stem cell medium. (b) RT-PCR was conducted and the mRNA
levels of diﬀerent liver-specific genes were examined. They are cytokeratin-18 (CK-18), hepatocyte nuclear factor 3b (HNF3b) and Abcc6,
respectively. Lane 1: cultured cells in diﬀerentiation-inducing medium; lane 2: cultured cells in stem cell culture medium; lane 3: MLE-10
(mouse liver epithelial cell line); lane 4: H2 O blank.

was observed in these cells while lower, barely detectable
levels were present in untransfected MSCs (Figure 4).
To evaluate cell migration in response to SDF-1, the
ligand for Cxcr4, we examined whether exogenous overexpression of Cxcr4 enhances the chemotaxis of MSCs
towards an SDF-1 gradient in a transwell migration assay.
Cxcr4 modification of MSCs increased the number of
cells migrating towards SDF-1 in a dose-dependent pattern
(Figure 5(a)). Specially, the number of migrated cells significantly increased at the dose of 30 and 60 ng/mL when
compared to that without adding SDF-1 (Figure 5(b)). Few
migrated cells were found in untransfected MSCs with all
diﬀerent dose settings of SDF-1 (data not shown). These data
indicate that overexpression of Cxcr4 enhances the ability of
MSCs to respond to SDF-1 induced chemotaxis.
3.3.2. The Levels of SDF-1 in the Liver and the Serum after
Partial Hepatectomy. To investigate how partial hepatectomy
aﬀects the levels of SDF-1 in the liver tissue or in the
blood, we first determined the temporal expression of SDF1 mRNA in the hepatectomized livers by quantitative RTPCR. SDF-1 increased at day 1 by more than 2-fold and
then decreased gradually to reach the baseline level as before
partial hepatecomy at day 7 (Figure 6(c)). Using the total
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RNA
2
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5

Figure 4: Overexpression of Cxcr4 in bone marrow derived
stem cells. The cells at passage 5 were transfected with a mouse
Cxcr4 expression vector (pCMV6-Cxcr4) and the stable cell clones
expressing Cxcr4 were established. RT-PCR was conducted to
examine the mRNA levels of mouse Crcx4 in the transfected or
untransfected stem cells at the same passage. Lane 0: 100 bp DNA
ladder; lane 1: reverse transcribed sample from the transfected cells;
lane 2: reverse transcribed sample from the untransfected cells; lane
3: nonreverse transcribed sample from the transfected cells; lane 4:
nonreverse transcribed sample from the untransfected cells; lane 5:
H2 O blank.
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Figure 5: In vitro migration of Cxcr4-MSCs. (a) Representative images of transmigrated Mesenchymal stem cells (MSCs) stably
overexpressing Cxcr4 in response to stromal-derived factor-1 (SDF-1) at concentrations of 0, 15, 30, or 60 ng/mL in transwell assay. (b)
Average number of cells migrated in transwell migration assay counted in 100x magnification field. Results are mean ± SEM of 3 diﬀerent
fields from 3 independent experiments. The asterisks indicate statistically significant diﬀerences, P < 0.05 (Student’s t-test).

liver protein extracts, ELISA showed a significant increase
in the hepatectomized livers at day 1 and then the levels
of SDF-1 quickly returned down to the baseline at day 3
and 7 after partial hepatectomy (Figure 6(d)), consistent with
the changes at mRNA levels. Conversely, the serum levels of
SDF-1 as measured by ELISA were decreased at 2 and 24
hours, and then returned to the baseline by 180 hours (day
7) (Figure 6(b)).
3.3.3. Homing of Transplanted MSCs towards the Liver.
At 24 hours after partial hepatectomy in immunodeficient Abcc6 −/− mouse model, Abcc6 −/− ; Rag1−/− , 5 × 105
Cxcr4-MSCs or unmodified MSCs were administrated by

intrasplenic injection. The transplanted mice were monitored for DiD-labeled MSCs for their migration towards
the liver by a live IVIS Luminar XR imaging system. DiD
is a fluorescent tracer which allows cells to be marked in
distinctive color detectable by the imaging machine. DiD
labeled MSCs were detected in the liver and spleen at day 1
and day 7 after transplantation (Figure 7(a)). The presence
of GFP-positive MSCs at day 7 in the liver was confirmed by
immunofluoresence using anti-GFP antibody (Figure 7(b)).
Moreover, to quantitate the percentage of migrated cells,
genomic DNA was isolated from the harvested liver at day
7 and qPCR was performed. Using a serially diluted GFP
DNA samples as the standards, the average percentage of
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Figure 6: The levels of SDF-1 in the liver or the serum after partial hepatectomy. Serum samples (b) or liver extracts (d) were obtained
from the mice at the diﬀerent time points after partial hepatectomy, and analyzed to determine the levels of SDF-1 using ELISA (n = 3–5).
The levels of SDF-1 were calculated based on the standard curve (a). RT-PCR was performed to examine the mRNA level of SDF-1 in the
hepatectomized livers (c).

(a)

(b)

Figure 7: Migration of MSCs towards the hepatectomized liver through splenic vein. 5 × 105 Cxcr4-MSCs labeled with Vybrant DiD
dye were administered to Abcc6 −/− ; Rag1−/− mice via spleen 24 hours after partial hepatectomy, and the livers were examined at day 7
of transplantation for the homing of the transplanted cells. (a) Representative fluorescence images of hepatectomized mice after MSCs
transplantation at Day 7 (lower panels). The images were examined from the ventral (left panels) and lateral (right panels) sides in
comparison with PBS injected hepatectomized mice as negative control (upper panels). (b) Six-μm frozen sections were examined by
immunofluoresence with an anti-GFP antibody, demonstrating the presence of GFP positive cells in the liver of mice at 7 days after
intrasplenic transplantation.
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Figure 8: Schematic depiction of liver targeting of MSCs through intrasplenic injection. GFP-transgenic mouse bone marrow derived MSCs,
which are positive for GFP, Sca-1, Cxcr4, and Abcc6, were injected through spleen 24 hours after partial hepatecotomy inducing release of
SDF-1, a ligand of Cxcr4. The presence of transplanted cells was observed by a live imaging system at day 7 posttransplantation through
ventral view (liver) and dorsal view (spleen).

GFP-positive Cxcr4-MSCs in the liver was 0.22%, whereas
it was 0.15% in the liver from mice transplanted with MSCs
without Cxcr4 transfection (data not shown).
The interaction of Cxcr4 and its ligand SDF-1 is reported
to play a major role in homing of MSCs into tissues [22].
Cells in the injured organs highly express SDF-1, causing
an elevation of localized SDF-1 levels, and the gradient of
SDF-1 recruits MSCs into the injury site via chemotactic
attraction through the interaction between SDF-1 and Cxcr4
[23, 24]. Thus, Cxcr4 has been recently used to enhance
homing and engraftment of stem cells through increasing
cell invasion in response to SDF-1 [23]. In this study, the
local expression of SDF-1 was induced by PHx and attracted
MSCs, especially Cxcr4-MSCs, toward the hepatectomized
liver. Increased SDF-1 concentration was shown in the liver,
but decreased SDF-1 in the blood, at 24 hours after PHx,
at which time point we delivered the cells. In the mouse
model of myocardial infarction, Abbott et al. reported that
the SDF-1 expression increased in the peri-infarct zone, but
its serum level decreased after the infarction, consistent with
our result [22]. This gradient of SDF-1 may contribute to the
recruitment of circulating progenitor cells expressing Cxcr4
into the hepatectomized liver (Figure 8).

4. Conclusions
The purpose of our study was to evaluate the potential of
MSCs to diﬀerentiate into hepatic cells and for their eﬃcient
recruitment to the liver in the setting of partial hepatectomy.
We intrasplenically delivered Lin− Sca1+ MSCs from Abcc6 +/+
GFP+ mice and identified donor cells by the presence of
GFP in the liver. We did confirm the capability of MSCs to
diﬀerentiate toward hepatocytic lineage in vitro by examining
hepatic specific gene expression at mRNA and protein levels,
including Abcc6 gene expression. We also observed homing
response to SDF-1, and overexpression of Cxcr4 resulted in a
significant additional increase in donor-cell migration both
in vitro and in vivo studies. The transplanted MSCs reside in
the recipient liver for at least up to 10 days.
Over the decades, many studies have utilized bone
marrow-derived cells for cell transplantation therapy in
animal models of various disorders. The reported treatment
eﬀects are variable, which may be related to diﬀerences in cell
type and quantity of transplanted cells, timing and approach
of cell transplantation and disorder model selection. Aurich
et al. demonstrated the presence of functional transplanted
cells in the recipient liver at 14 weeks after administration of
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human bone marrow MSCs through intrasplenic injection
using an immunodeficient Pfp−/− /Rag2−/− mouse model,
which has malfunction of NK cells and depletion of mature B
and T cells [25]. The long term presence of transplanted cells
in recipient liver may depend on the background of recipient
mice and kind of transplanted MSCs, which requires further
long term study.
Immune rejection is a potential problem of cell transplantation for treatment of patients. To overcome immune
rejection, or to avoid it, the stem cells must either be derived
from the recipient or identical twin, or the stem cells must
be engineered in a way to circumvent the immune reaction.
Currently, the approach that appears most promising entails
using embryonic stem cells whose DNA has been replaced
with the recipient’s DNA, thus becoming “self ”, the so-called
therapeutic cloning [26].
In summary, these data suggest that purified MSCs have
the capability of diﬀerentiating into hepatic lineages and
homing to the liver. The interactions between SDF-1 and
Cxcr4 could be a critical mechanism to recruit MSCs for liver
targeting and regeneration, and further studies will define the
optimal conditions to maintain and propagate MSCs in the
target organs, such as in the liver in case of PXE.
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